Stay updated with breaking news from Role Function Restrictive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
If approved by the European Commission (EC), atogepant will be the first and only once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) for the prophylaxis of migraine in adults who have four or m...
QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded...
Galcenzumab at a dose of 120 mg/month showed greater safety and efficacy in the prevention of episodic migraine compared with placebo.
ABBVie today announced that the New England Journal of Medicine has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The study, which enrolled adult participants experiencing 4 to 14 migraine days per month, found that all active treatment arms of atogepant 10 mg, 30 mg, and 60 mg once-daily ...